Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 27, 2020

Dosing commences in Phase III trial of Moderna’s Covid-19 vaccine

Moderna has started dosing participants in the Phase III clinical trial of its Covid-19 vaccine candidate, mRNA-1273.

Moderna has started dosing participants in the Phase III clinical trial of its Covid-19 vaccine candidate, mRNA-1273.

The study, named COVE, is being performed in alliance with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

During the randomised, placebo-controlled trial, a 100µg dose of the vaccine candidate will be assessed in around 30,000 participants in the US.

The primary endpoint will be the prevention of symptomatic Covid-19, while key secondary endpoints include the prevention of severe Covid-19 and infection by SARS-CoV-2, irrespective of symptomology.

Moderna said that the primary efficacy analysis of the trial will be event-driven and depend on the number of participants with symptomatic Covid-19.

An independent Data and Safety Monitoring Board will review the study results.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Moderna CEO Stephane Bancel said: “We are pleased to have started the Phase III COVE study. We are grateful to the efforts of so many inside and outside the company to get us to this important milestone.

“We look forward to this trial demonstrating the potential of our vaccine to prevent Covid-19, so that we can defeat this pandemic.”

The company is working with contract research organisation PPD to conduct the COVE study. PPD supported the Phase II trial of the vaccine candidate, which completed the enrolment of 600 participants at eight sites within one month.

Moderna has chosen almost 100 sites with representative demography and is working with those sites to enrol volunteers at increased risk of Covid-19 infection.

An interim analysis of a Phase I trial assessing the Covid-19 vaccine candidate found the product to be generally safe and well-tolerated. The findings have been published in the New England Journal of Medicine.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU